Faster-than-expected FDA approval of Roche’s vismodegib
31 January 2012
FDA priority review for Roche/Genentech’s vismodegib for skin cancer
10 November 2011
Showing 1-4 of 4 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
